Skye Bioscience, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Skye Bioscience, Inc. (SKYE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 178.91 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-03-10
- Skye Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2022-09-30 was 0.00 shares.
- Skye Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2022-06-30 was 106.25K shares.
- Skye Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2022-03-31 was 215.00K shares.
- Skye Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2021-09-30 was -713.75K shares.
- Skye Bioscience, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 178.91K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 178.91K shares 10-K · filed 2026-03-10 | |||
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 106.25K shares derived: sum of 2 quarters · filed 2022-11-14 | 321.25K shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 106.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 321.25K shares 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | 215.00K shares 10-Q · filed 2022-05-06 | |||
| 2021-09-30 | -713.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 40.00K shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 753.75K shares 10-Q · filed 2021-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |